Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
45
GSK Quote, Financials, Valuation and Earnings
Last price:
$49.63
Seasonality move
:
6.45%
Day range:
$49.07 - $49.63
52-week range:
$31.72 - $49.63
Dividend yield:
3.38%
P/E ratio:
14.15x
P/S ratio:
2.43x
P/B ratio:
4.59x
Volume:
3.5M
Avg. volume:
3.6M
1-year change:
46.19%
Market cap:
$99.7B
Revenue:
$40.1B
EPS (TTM):
$3.51
Analysts' Opinion
-
Consensus RatingGSK Plc has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 5 Hold ratings, and 1 Sell rating.
-
Price Target DownsideAccording to analysts' consensus price target of $49.35, GSK Plc has an estimated downside of -0.57% from its current price of $49.63.
-
Price Target UpsideAccording to analysts, the highest upside price target is $58.00 representing -100% upside increase from its current price of $49.63.
Fair Value
-
According to the consensus of 7 analysts, GSK Plc has -0.57% downside to fair value with a price target of $49.35 per share.
GSK vs. S&P 500
-
Over the past 5 trading days, GSK Plc has overperformed the S&P 500 by 2.43% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
GSK Plc does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
GSK Plc has grown year-over-year revenues for 10 quarters straight. In the most recent quarter GSK Plc reported revenues of $11.5B.
Earnings Growth
-
GSK Plc has grown year-over-year earnings for 4 quarters straight. In the most recent quarter GSK Plc reported earnings per share of $1.32.
Enterprise value:
118.6B
EV / Invested capital:
--
Price / LTM sales:
2.43x
EV / EBIT:
12.01x
EV / Revenue:
2.82x
PEG ratio (5yr expected):
0.11x
EV / Free cash flow:
21.02x
Price / Operating cash flow:
18.13x
Enterprise value / EBITDA:
8.16x
Gross Profit (TTM):
$30.5B
Return On Assets:
10.09%
Net Income Margin (TTM):
18.93%
Return On Equity:
42.84%
Return On Invested Capital:
19.21%
Operating Margin:
30.08%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $36.4B | $39.7B | $42.1B | $10.4B | $11.5B | |
| Gross Profit | $26.2B | $28B | $30.5B | $7.4B | $8.5B | |
| Operating Income | $8.2B | $7.3B | $9.9B | $618.8M | $3.5B | |
| EBITDA | $10.3B | $11.5B | $14.5B | $1.9B | $4.5B | |
| Diluted EPS | $3.64 | $1.54 | $3.51 | -$0.04 | $1.32 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $24.6B | $22.6B | $25.9B | $23.2B | $24B | |
| Total Assets | $106.1B | $67.3B | $74.3B | $77.9B | $82.6B | |
| Current Liabilities | $30.2B | $23.4B | $27.3B | $28.8B | $28.7B | |
| Total Liabilities | $76.8B | $57.6B | $58.9B | $59.8B | $61.4B | |
| Total Equity | $29.3B | $9.7B | $15.4B | $18B | $21.2B | |
| Total Debt | $34.5B | $21.6B | $19.5B | $17.8B | $20.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $6B | $8.6B | $9.8B | $2.7B | $3B | |
| Cash From Investing | -$3.1B | $9.4M | -$6.1B | -$952.6M | -$2.2B | |
| Cash From Financing | -$3.3B | -$8.5B | -$4.1B | -$1.5B | -$1.7B | |
| Free Cash Flow | $3.2B | $5.4B | $5.6B | $1.7B | $1.8B | |
GSK
Sector
Market Cap
$99.7B
$28.2M
Price % of 52-Week High
100%
50.98%
Dividend Yield
3.38%
0%
Shareholder Yield
4.91%
-1.55%
1-Year Price Total Return
46.19%
-17.58%
Beta (5-Year)
0.473
0.498
Dividend yield:
3.38%
Annualized payout:
$1.56
Payout ratio:
30.44%
Growth streak:
1 years
Technicals
8-day SMA
Buy
Level
$49.07
200-day SMA
Buy
Level
$41.27
Bollinger Bands (100)
Buy
Level
40.77 - 47.97
Chaikin Money Flow
Buy
Level
468.6M
20-day SMA
Buy
Level
$48.75
Relative Strength Index (RSI14)
Buy
Level
62.82
ADX Line
Buy
Level
13.1
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$47.55
MACD (12, 26)
Buy
Level
0.53
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Neutral
Level
91.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.6605)
Sell
CA Score
(Annual)
Level (-1.068)
Buy
Beneish M-Score
(Annual)
Level (-2.7996)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (0.8344)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Stock Forecast FAQ
In the current month, GSK has received 1 Buy ratings 5 Hold ratings, and 1 Sell ratings. The GSK average analyst price target in the past 3 months is $49.35.
-
Where Will GSK Plc Stock Be In 1 Year?
According to analysts, the consensus estimate is that GSK Plc share price will drop to $49.35 per share over the next 12 months.
-
What Do Analysts Say About GSK Plc?
Analysts are divided on their view about GSK Plc share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that GSK Plc is a Sell and believe this share price will rise from its current level to $40.00.
-
What Is GSK Plc's Price Target?
The price target for GSK Plc over the next 1-year time period is forecast to be $49.35 according to 7 Wall Street analysts, 1 of them rates the stock a Buy, 1 rates the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is GSK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for GSK Plc is a Hold. 5 of 7 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of GSK?
You can purchase shares of GSK Plc via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase GSK Plc shares.
-
What Is The GSK Plc Share Price Today?
GSK Plc was last trading at $49.63 per share. This represents the most recent stock quote for GSK Plc. Yesterday, GSK Plc closed at $49.63 per share.
-
How To Buy GSK Plc Stock Online?
In order to purchase GSK Plc stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get GSK Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GSK
Sector
P/E ratio
14.15x
24.09x
PEG ratio
0.11x
-0.01x
P/B ratio
4.59x
1.81x
Price / LTM sales
2.43x
1.59x
Growth Metrics
GSK
Sector
Revenue growth
10.64%
4.68%
Earnings growth
3676.49%
11.06%
Revenue (5-year growth)
-1.42%
6.45%
Earnings forecast
$0.61
-$0.18
Profitability
GSK
Sector
Profitability FY 2024
$28B
$3.6M
Return on invested capital
19.21%
-31.84%
Return on assets
10.09%
-28.18%
Return on equity
42.84%
-37.63%
Earnings Date
Last Earnings Date
Oct
29
Next Earnings Date
Feb
4
Estimated Next Earnings Date
Jan
28
Balance Sheet
GSK
Sector
Total cash
$4.5B
$26.3M
Short term investments
$26.4M
$26M
Total assets
$74.5B
$76.7M
Long term debt
$20.1B
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
45
CTEV alert for Jan 2
Claritev Corp. [CTEV] is down 20.7% over the past day.
Sell
47
ASTS alert for Jan 2
AST Spacemobile, Inc. [ASTS] is up 14.94% over the past day.
Buy
60
BIDU alert for Jan 3
Baidu, Inc. [BIDU] is up 15.01% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
